Genetic basis of Parkinson disease. 2010

Georgia Xiromerisiou, and Efthimios Dardiotis, and Vaïa Tsimourtou, and Persa Maria Kountra, and Konstantinos N Paterakis, and Eftychia Z Kapsalaki, and Kostas N Fountas, and Georgios M Hadjigeorgiou
Institute for Biomedical Technology (BIOMED), Centre for Research and Technology-Thessaly (CERETETH), Larussa, Greece.

Over the past few years, considerable progress has been made in understanding the molecular mechanisms of Parkinson disease (PD). Mutations in certain genes are found to cause monogenic forms of the disorder, with autosomal dominant or autosomal recessive inheritance. These genes include alpha-synuclein, parkin, PINK1, DJ-1, LRRK2, and ATP13A2. The monogenic variants are important tools in identifying cellular pathways that shed light on the pathogenesis of this disease. Certain common genetic variants are also likely to modulate the risk of PD. International collaborative studies and meta-analyses have identified common variants as genetic susceptibility risk/protective factors for sporadic PD.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011494 Protein Kinases A family of enzymes that catalyze the conversion of ATP and a protein to ADP and a phosphoprotein. Protein Kinase,Kinase, Protein,Kinases, Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071617 Protein Deglycase DJ-1 A protein deglycase that repairs methylglyoxal- and glyoxal-glycated amino acids and proteins, releasing repaired proteins and lactate or glycolate. It deglycates CYSTEINE, ARGININE and LYSINE residues to reactivate proteins by reversing glycation and prevent the formation of ADVANCED GLYCATION END PRODUCTS. It protects cells against OXIDATIVE STRESS and CELL DEATH by functioning as an oxidative stress sensor and redox-sensitive MOLECULAR CHAPERONE and PROTEASE. Mutations in the PARK7 gene are associated with autosomal-recessive, early-onset PARKINSON DISEASE. DJ-1 Protein,DJ-1-PARK7 Protein,DJ1 Protein,PARK7 Protein,Parkinson Protein 7,Parkinsonism Associated Deglycase,DJ 1 PARK7 Protein,DJ 1 Protein,DJ-1, Protein Deglycase,Deglycase, Parkinsonism Associated
D014644 Genetic Variation Genotypic differences observed among individuals in a population. Genetic Diversity,Variation, Genetic,Diversity, Genetic,Diversities, Genetic,Genetic Diversities,Genetic Variations,Variations, Genetic
D015513 Oncogene Proteins Proteins coded by oncogenes. They include proteins resulting from the fusion of an oncogene and another gene (ONCOGENE PROTEINS, FUSION). Oncogene Products,Oncoprotein,Oncoproteins,Oncogene Product,Oncogene Protein,Product, Oncogene,Products, Oncogene,Protein, Oncogene,Proteins, Oncogene
D044767 Ubiquitin-Protein Ligases A diverse class of enzymes that interact with UBIQUITIN-CONJUGATING ENZYMES and ubiquitination-specific protein substrates. Each member of this enzyme group has its own distinct specificity for a substrate and ubiquitin-conjugating enzyme. Ubiquitin-protein ligases exist as both monomeric proteins multiprotein complexes. Ubiquitin-Protein Ligase,E3 Ligase,E3 Ubiquitin Ligase,Ubiquitin Ligase E3,Ubiquitin-Protein Ligase E3,Ligase E3, Ubiquitin,Ligase E3, Ubiquitin-Protein,Ligase, E3,Ligase, E3 Ubiquitin,Ligase, Ubiquitin-Protein,Ligases, Ubiquitin-Protein,Ubiquitin Ligase, E3,Ubiquitin Protein Ligase,Ubiquitin Protein Ligase E3,Ubiquitin Protein Ligases
D046690 Deep Brain Stimulation Therapy for MOVEMENT DISORDERS, especially PARKINSON DISEASE, that applies electricity via stereotactic implantation of ELECTRODES in specific areas of the BRAIN such as the THALAMUS. The electrodes are attached to a neurostimulator placed subcutaneously. Brain Stimulation, Deep,Electrical Stimulation of the Brain,Brain Stimulations, Deep,Deep Brain Stimulations,Stimulation, Deep Brain,Stimulations, Deep Brain

Related Publications

Georgia Xiromerisiou, and Efthimios Dardiotis, and Vaïa Tsimourtou, and Persa Maria Kountra, and Konstantinos N Paterakis, and Eftychia Z Kapsalaki, and Kostas N Fountas, and Georgios M Hadjigeorgiou
November 2010, Rinsho shinkeigaku = Clinical neurology,
Georgia Xiromerisiou, and Efthimios Dardiotis, and Vaïa Tsimourtou, and Persa Maria Kountra, and Konstantinos N Paterakis, and Eftychia Z Kapsalaki, and Kostas N Fountas, and Georgios M Hadjigeorgiou
July 2009, Biochimica et biophysica acta,
Georgia Xiromerisiou, and Efthimios Dardiotis, and Vaïa Tsimourtou, and Persa Maria Kountra, and Konstantinos N Paterakis, and Eftychia Z Kapsalaki, and Kostas N Fountas, and Georgios M Hadjigeorgiou
January 2011, Nature reviews. Neurology,
Georgia Xiromerisiou, and Efthimios Dardiotis, and Vaïa Tsimourtou, and Persa Maria Kountra, and Konstantinos N Paterakis, and Eftychia Z Kapsalaki, and Kostas N Fountas, and Georgios M Hadjigeorgiou
June 2010, Archives of neurology,
Georgia Xiromerisiou, and Efthimios Dardiotis, and Vaïa Tsimourtou, and Persa Maria Kountra, and Konstantinos N Paterakis, and Eftychia Z Kapsalaki, and Kostas N Fountas, and Georgios M Hadjigeorgiou
February 2002, JAMA,
Georgia Xiromerisiou, and Efthimios Dardiotis, and Vaïa Tsimourtou, and Persa Maria Kountra, and Konstantinos N Paterakis, and Eftychia Z Kapsalaki, and Kostas N Fountas, and Georgios M Hadjigeorgiou
January 2018, Frontiers in aging neuroscience,
Georgia Xiromerisiou, and Efthimios Dardiotis, and Vaïa Tsimourtou, and Persa Maria Kountra, and Konstantinos N Paterakis, and Eftychia Z Kapsalaki, and Kostas N Fountas, and Georgios M Hadjigeorgiou
December 2016, Neurology,
Georgia Xiromerisiou, and Efthimios Dardiotis, and Vaïa Tsimourtou, and Persa Maria Kountra, and Konstantinos N Paterakis, and Eftychia Z Kapsalaki, and Kostas N Fountas, and Georgios M Hadjigeorgiou
October 2010, Neuron,
Georgia Xiromerisiou, and Efthimios Dardiotis, and Vaïa Tsimourtou, and Persa Maria Kountra, and Konstantinos N Paterakis, and Eftychia Z Kapsalaki, and Kostas N Fountas, and Georgios M Hadjigeorgiou
July 2009, Pediatric surgery international,
Georgia Xiromerisiou, and Efthimios Dardiotis, and Vaïa Tsimourtou, and Persa Maria Kountra, and Konstantinos N Paterakis, and Eftychia Z Kapsalaki, and Kostas N Fountas, and Georgios M Hadjigeorgiou
September 1995, The Journal of pediatrics,
Copied contents to your clipboard!